Rapid Briefs
VV catches the signal early, explains it cleanly, shows the source trail, and tells you what not to overclaim.
Filtered signal trail
Riaan Singh Digeorge became the first reported patient to receive experimental AAV9 gene therapy for Cockayne syndrome after a parent-led development effort.
Why now
The first-patient milestone turns an ultra-rare parent-led research program into a live human gene-therapy story.
CIRM awarded $4.9 million to advance FRF-001, an AAV9 gene therapy for FOXG1 syndrome, through a Phase 1/2 clinical trial.
Why now
Parent-led foundations are increasingly becoming drug-development engines for devastating rare pediatric disorders.
Riaan Singh Digeorge received an experimental AAV9 gene therapy after a parent-led rare-disease development effort raised millions and reached an FDA-cleared IND.
Why now
A parent-led effort moved an ultra-rare disease from no approved treatment to first-in-human dosing, making the development story as important as the science.
